Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.58 |
| ▸ | BCHE | P06276 | 8/20 | 0.57 |
| ▸ | BACE1 | P56817 | 8/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239922 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| SCHEMBL42501 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| SCHEMBL14793661 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| Bromide SCHEMBL2495449 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL697482 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL2905438 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL20183286 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Bromide SCHEMBL2899465 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Acetic Acid SCHEMBL2500600 | 0.91 | ACHE (0.53) | ACHELTA4HALDH1A1SIGMAR1DRD2 | |
| Acetic Acid SCHEMBL2904677 | 0.91 | ACHE (0.53) | ACHELTA4HALDH1A1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598504-A2 | MICROPARTICLE AND IMPLANT FORMULATIONS FOR CGMP ANALOG THERAPY | Mireca Medicines GmbH (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2024074585-A2 | MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY | MIRECA MEDICINES GMBH (DE) | 2024-04-11 | — | — | WO | claimed |
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | claimed |
| EP-2623593-B1 | NOVEL AMINOTRANSFERASE AND GENE ENCODING SAME, AND USE OF THE AMINOTRANSFERASE AND THE GENE | KANEKA CORP (JP) | 2017-07-12 | — | — | EP | claimed |
| EP-2623595-B1 | NOVEL TRANSAMINASE SHOWING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR UTILIZATION THEREOF | KANEKA CORP (JP) | 2016-11-02 | — | — | EP | claimed |
| US-9481871-B2 | Nucleic acid encoding a polpeptide having aminotransferase activity, vectors and host cells comprising the nucleic acid | KANEKA CORPORATION (JP) | 2016-11-01 | — | — | US | claimed |
| US-9481870-B2 | Nucleic acid encoding a polypeptide having aminotransferase activity, vectors and host cells comprising the nucleic acid | KANEKA CORPORATION (JP) | 2016-11-01 | — | — | US | claimed |
| CN-102603592-B | Preparation method for (R)-1-benzyl-3-aminopyrrolidine and (S)-1-benzyl-3-aminopyrrolidine | SHANGHAI INST TECHNOLOGY | 2014-08-20 | — | — | CN | claimed |
| CN-103534350-A | Novel aminotransferase exhibiting high activity for glutamic acid, gene encoding the same, and method for using the same | KANEKA CORP | 2014-01-22 | — | — | CN | claimed |
| US-20130210092-A1 | Novel Transaminase, Gene Encoding the Same, and Method Using Them | KANEKA CORPORATION (JP) | 2013-08-15 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| JP-3264928-B2 | — | — | 2002-03-11 | — | — | JP | claimed |
| EP-0638068-B1 | PROCESS FOR THE MANUFACTURE OF (S)-3-AMINO-1-SUBSTITUTED-PYRROLIDINES | WARNER LAMBERT CO (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0638068-A1 | PROCESS FOR THE MANUFACTURE OF (S)-3-AMINO-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1993022283-A1 | PROCESS FOR THE MANUFACTURE OF (S)-3-AMINO-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1993-11-11 | — | — | WO | claimed |
| US-5177217-A | Process for the manufacture of (S)-3-amino-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| EP-0391169-A2 | Enantiomeric pure 7-(3-amino-1-pyrrolidinyl)-chinolon-and-naphthyridon carboxylic acids | BAYER AG (DE) | 1990-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ACHE 3513/4885BCHE 3091/4885BACE1 4477/4885 |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | ACHE 2842/4885BCHE 1083/4885BACE1 724/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | ACHE 3424/4885BCHE 1045/4885BACE1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.